Lupin Launches Empagliflozin Linagliptin FDC, AjaDuo At Affordable Prices

Approved by the Drug Controller General of India (DCGI), the FDC is supported by major global clinical trials, including EMPA-REG and CARMELINA, demonstrating significant cardiovascular benefits. The combination therapy has been shown to provide a 38% reduction in cardiovascular mortality and a 14% reduction in 3P MACE (Major Adverse Cardiovascular Events) in major trials, reinforcing its role in comprehensive diabetes management.

Commenting on the launch, Mr Gagan Arora, Vice President Sales and Marketing at Lupin, said, "At Lupin, we are committed to delivering innovative healthcare solutions that uphold our philosophy – Think Globally, Buy Locally – Global Quality at Indian Price. With Ajaduo®, we reaffirm its commitment to ensuring that essential therapies more accessible to the patients in need.”

Lupin has been marketing AJADUO® for the past 7 years in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. With the expiry of patent on Empagliflozin in India, Lupin is making the drug available at more affordable prices. Ajaduo 10/5 (containing Empagliflozin (10 mg) + Linagliptin (5 mg) will be available at Rs 19.80 per tablet and Ajaduo 25/5 (Empagliflozin (25 mg) + Linagliptin (5 mg) at Rs 20.78 per tablet

“For diabetes treatment, Ajaduo with Global Quality will now be better accessible to Indian Diabetic patients at an affordable price,” Mr Arora added.